Moleculin Biotech Inc (NAS:MBRX)

$ 2.64 0.13 (5.18%) Market Cap: 7.51 Mil Enterprise Value: -3.29 Mil PE Ratio: 0 PB Ratio: 0.38 GF Score: 32/100

Q3 2024 Moleculin Biotech Inc Earnings Call Transcript
1 day ago

$2.51 (-1.57%)

Earnings
Q2 2024 Moleculin Biotech Inc Earnings Call Transcript
Aug 06, 2024

$2.2 (-8.71%)

Earnings
Q1 2024 Moleculin Biotech Inc Earnings Call Transcript
May 13, 2024

$4.67 (-1.89%)

Earnings
Q4 2023 Moleculin Biotech Inc Earnings Call Transcript
Mar 25, 2024

$5.25 (-7.97%)

Earnings
Q3 2023 Moleculin Biotech Inc Earnings Call Transcript
Nov 13, 2023

$8.64 (+6.70%)

Earnings
Moleculin Biotech Inc Participate in the Virtual Investor Ask the CEO Conference Transcript
Oct 24, 2023
Moleculin Biotech Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Q2 2023 Moleculin Biotech Inc Earnings Call Transcript
Aug 11, 2023

$9.26 (-1.98%)

Earnings
Q1 2023 Moleculin Biotech Inc Earnings Call Transcript
May 11, 2023

$11.28 (-3.59%)

Earnings
Q4 2022 Moleculin Biotech Inc Earnings Call Transcript
Mar 23, 2023

$14.15 (-8.44%)

Earnings
Moleculin Biotech Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Moleculin Biotech Inc At the Virtual Investor 2023 Companies to Watch Event Transcript
Jan 17, 2023
Q3 2022 Moleculin Biotech Inc Earnings Call Transcript
Nov 10, 2022

$13.51 (+0.64%)

Earnings
Moleculin Biotech Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021

Q4 2023 Moleculin Biotech Inc Earnings Call Transcript

Mar 25, 2024 / 12:30PM GMT

Release Date Price: $5.25 (-7.97%)

Transcript 8-K10-K

Operator

Greetings. Welcome to the Moleculin Biotech 2023 year end conference call. And webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to Jenene Thomas, Investor Relations. Thank you. You may begin.

Jenene Thomas

Moleculin Biotech Inc - Investor Relations

Thank you, Daryl, and good morning and welcome, everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations or future projections. These are forward-looking statements and involve risks and uncertainties. Forward looking statements on this call are made pursuant to the Safe Harbor provisions of the federal securities laws and are based on molecular its current expectations and actual results could differ materially. As a result, you should

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.